This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n6http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q87269919
rdf:type
wikibase:Item
schema:description
wetenschappelijk artikel article scientifique publié en 2014 scientific article published on 10 February 2014 наукова стаття, опублікована в лютому 2014 2014 թվականի փետրվարի 10-ին հրատարակված գիտական հոդված artículu científicu espublizáu en febreru de 2014
p:P577
wds:Q87269919-6DCFE2C9-C9F4-4C3A-A303-431C3C2C1036
wdt:P577
2014-02-10T00:00:00Z
p:P2093
wds:Q87269919-4153106F-2B93-41EA-953D-A54AA3A95488 wds:Q87269919-35FF9134-B5BA-4316-BA30-A4697C1588A3 wds:Q87269919-92C71041-3EE7-4B36-A066-AF1F318AC852 wds:Q87269919-ECCF095F-AC9D-4D5D-9A54-9BF8517596B4
wdt:P2093
Sandra J Horning Yasodha Natkunam John Allen Sarah Daadi
rdfs:label
Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma
skos:prefLabel
Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma
schema:name
Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma
p:P50
wds:Q87269919-01AB089C-D525-4C30-B02D-70BF7041033F wds:Q87269919-51B80AAB-E67E-4406-8AA1-2FF01DE6D37B wds:Q87269919-FCC8CBDA-8449-4254-9B05-C770B447E1FC
wdt:P50
wd:Q91183516 wd:Q60545128 wd:Q102148850
p:P1476
wds:Q87269919-A8FD072F-291C-4F82-B15C-8D5CEC89D68F
wdt:P1476
Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma
p:P304
wds:Q87269919-B6D475CB-B9E5-4B73-92B9-71777A3BEF20
wdt:P304
912-918
p:P31
wds:Q87269919-66D6E826-1901-4C19-87F9-F65E4098B262
wdt:P31
wd:Q13442814
p:P921
wds:Q87269919-9029C98E-E1E5-4840-8E12-6923E171D4DE wds:Q87269919-9B5AC786-C3B1-4116-B533-DFAAE221E8E4
wdt:P921
wd:Q412323 wd:Q209369
p:P698
wds:Q87269919-C6FBC53C-5B40-4213-B60F-84BE454CC027
wdtn:P698
n12:24516013
wdt:P698
24516013
p:P1433
wds:Q87269919-CE84683F-A41D-4132-8A4B-CEE912896588
wdt:P1433
wd:Q400292
p:P433
wds:Q87269919-BD48135F-B8DC-4A5C-82C2-A465CA786BC0
p:P478
wds:Q87269919-5DD3AE04-F2DF-4E34-A93B-EB3C235E8AAB
wdt:P433
9
wdt:P478
32
p:P356
wds:Q87269919-80EB438F-5241-4A06-B84A-C3643011F3CE
wdtn:P356
n6:JCO.2013.53.2069
wdt:P356
10.1200/JCO.2013.53.2069